United Therapeutics Corp (UTHR): Martine A Rothblatt , Chairman & Co-CEO of United Therapeutics Corp sold 5,546 shares on Apr 21, 2016. The Insider selling transaction was reported by the company on Apr 25, 2016 to the Securities and Exchange Commission. The shares were sold at $116.01 per share for a total value of $641,921.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 18, 2016, Martine A Rothblatt (Chairman & Co-CEO) sold 5,547 shares at $114.30 per share price.On Apr 4, 2016, Raymond Dwek (director) sold 3,000 shares at $110.79 per share price.Also, On Mar 3, 2016, Tommy G Thompson (director) sold 3,000 shares at $126.54 per share price.On Nov 4, 2015, Richard Giltner (director) sold 7,500 shares at $153.22 per share price.
United Therapeutics Corporation: On Friday, Apr 22, 2016 heightened volatility was witnessed in United Therapeutics Corporation which led to swings in the share price. The shares opened for trading at $117.9 and hit $119.74 on the upside , eventually ending the session at $119.61, with a gain of 1.67% or 1.96 points. The heightened volatility saw the trading volume jump to 5,15,014 shares. The 52-week high of the share price is $190.13 and the company has a market cap of $5,425 M . The 52-week low of the share price is at $107.04.
Company has been under the radar of several Street Analysts.United Therapeutics Corporation is Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 122 from a previous price target of $150 . The Rating was issued on Apr 11, 2016.United Therapeutics Corporation is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 229 from a previous price target of $238 . The Rating was issued on Mar 28, 2016.United Therapeutics Corporation is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 238 from a previous price target of $244 . The Rating was issued on Mar 2, 2016.United Therapeutics Corporation is Upgraded by Standpoint Research to Buy and the brokerage firm has set the Price Target at $148. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 10, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.